Unmasking the nature of granulomatosis with polyangiitis – a diagnostic odyssey revealed through a compelling case report
DOI:
https://doi.org/10.15584/ejcem.2024.2.27Keywords:
autoimmune diseases, granulomatosis with polyangiitis, vasculitisAbstract
Introduction and aim. Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, presents a formidable challenge in the realm of autoimmune diseases. Granulomatosis, characterized by vasculitis and granuloma formation, exhibits diverse clinical manifestations. The rarity of GPA is evident, with an estimated incidence between 0.4 and 11.9 cases per 1 million person-years. The aim of this report is to show the complex diagnostic challenges inherent in GPA, demonstrating the diagnostic process from initial symptoms.
Description of the case. This case report unfolds the diagnostic journey of a 52-year-old Caucasian male. The presented case, initially suspected as a respiratory infection, led to a comprehensive investigation owing to persistent symptoms, abnormal blood counts, and elevated inflammatory markers. This narrative aims to depict the patient’s diagnostic journey. Key diagnostic tools include ANCA testing, imaging studies, and tissue biopsy. Pulmonary nodules, lymphangitic changes, and renal involvement culminating in a GPA diagnosis confirmed by positive ANCA and anti-PR3 antibodies. The successful management of this case involved a tailored therapeutic regimen, including cyclophosphamide and methylprednisolone, addressing both vasculitic and renal components.
Conclusion. This case contributes to the understanding of atypical presentations of GPA, emphasizing the importance of a holistic and dynamic diagnostic approach.
Downloads
References
Manti F, Battaglia C, Pelaia C, Petullà M, Bertucci B, Laganà D. Migrant cavitation as primary involvement in a particular case of granulomatosis with polyangiitis. Radiol Case Rep. 2022;17(10):3535-3538. doi: 10.1016/j.radcr.2022.06.074
Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13(11):1121-1125. doi: 10.1016/j.autrev.2014.08.017
Panupattanapong S, Stwalley DL, White AJ, Olsen MA, French AR, Hartman ME. Epidemiology and Outcomes of Granulomatosis With Polyangiitis in Pediatric and Working-Age Adult Populations In the United States: Analysis of a Large National Claims Database. Arthritis Rheumatol. 2018;70(12):2067-2076. doi: 10.1002/art.40577
Austin K, Janagan S, Wells M, Crawshaw H, McAdoo S, Robson JC. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives. J Inflamm Res. 2022;15:2567-2582. doi: 10.2147/JIR.S284768
Kanecki K, Nitsch-Osuch A, Gorynski P, Tarka P, Bogdan M, Tyszko P. Epidemiology of Granulomatosis with Polyangiitis in Poland, 2011-2015. Adv Exp Med Biol. 2018;1116:131-138. doi: 10.1007/5584_2018_239
Kain R, Exner M, Brandes R, et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008;14(10):1088-1096. doi: 10.1038/nm.1874
Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71. doi: 10.1038/s41572-020-0204-y
Kronbichler A, Lee KH, Denicolò S, et al. Immunopathogenesis of ANCA-Associated Vasculitis. Int J Mol Sci. 2020;21(19):7319. doi: 10.3390/ijms21197319
Frangou E, Vassilopoulos D, Boletis J, Boumpas DT. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev. 2019;18(8):751-760. doi: 10.1016/j.autrev.2019.06.011
Trivioli G, Marquez A, Martorana D, et al. Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management. Nat Rev Rheumatol. 2022;18(10):559-574. doi: 10.1038/s41584-022-00819-y
Guchelaar NAD, Waling MM, Adhin AA, van Daele PLA, Schreurs MWJ, Rombach SM. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun Rev. 2021;20(1):102716. doi: 10.1016/j.autrev.2020.102716
Cabral DA, Uribe AG, Benseler S, et al. Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum. 2009;60(11):3413-3424. doi: 10.1002/art.24876
Morales-Angulo C, García-Zornoza R, Obeso-Agüera S, Calvo-Alén J, González-Gay MA. Manifestaciones otorrinolaringológicas en pacientes con granulomatosis de Wegener (granulomatosis con poliangeitis) [Ear, nose and throat manifestations of Wegener's granulomatosis (granulomatosis with polyangiitis)]. Acta Otorrinolaringol Esp. 2012;63(3):206-211. doi: 10.1016/j.otorri.2011.12.002
Jeleniewicz R, Suszek D, Majdan M. Musculoskeletal symptoms in a group Of granulomatosis with polyangiitis patients. Wiad Lek. 2018;71(1 pt 1):17-20.
Gomes GL, Halpern AS, Souza FH, Shinjo SK. Association between saddle nose deformity and retro-orbital mass in Wegener's granulomatosis. Acta Reumatol Port. 2010;35(3):340-345.
Byszewska A, Skrzypiec I, Rymarz A, Niemczyk S, Rękas M. Ocular Involvement of Granulomatosis with Polyangiitis. J Clin Med. 2023;12(13):4448. doi: 10.3390/jcm12134448
Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC. Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol. 2009;27(1 Suppl 52):65-69.
Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315-320. doi: 10.1136/annrheumdis-2021-221795
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83(1):30-47. doi: 10.1136/ard-2022-223764
Robson JC, Dawson J, Cronholm PF, et al. Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Int. 2018;38(4):675-682. doi: 10.1007/s00296-017-3855-6
Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. doi: 10.1056/NEJMoa0909905
Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-427. doi: 10.1056/NEJMoa1213277
de Joode AAE, Sanders JSF, Puéchal X, et al. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology (Oxford). 2017;56(11):1894-1901. doi: 10.1093/rheumatology/kex281
Alesaeidi S, Darvishi M, Dabiri S, GhasemiAdl M, Jafarieh A, Tavakolpour S. Current Understanding and Unknown Aspects of the Treatment of Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Opportunities for Future Studies. Curr Rheumatol Rev. 2020;16(4):257-266. doi: 10.2174/1573397116666200331130919
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609. doi: 10.1056/NEJMoa2023386
Gendelman O, Kuntzman Y, Shovman O, et al. Tumor-like Lesions in Patients with Granulomatosis with Polyangiitis: A Case Series. Isr Med Assoc J. 2021;23(6):350-352.
Walters GD, Willis NS, Cooper TE, Craig JC. Interventions for renal vasculitis in adults. Cochrane Database Syst Rev. 2020;1(1):CD003232. doi: 10.1002/14651858.CD003232.pub4
Luna M, Bocanegra V, Vallés PG. Granulomatosis with polyangiitis: rapidly progressive necrotizing glomerulonephritis in a pediatric patient. Int J Nephrol Renovasc Dis. 2014;7:153-156. doi: 10.2147/IJNRD.S57109
Kronbichler A, Kerschbaum J, Gopaluni S, et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2018;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
